Skip to main navigation
Skip to search
Skip to main content
The Rotterdam Eye Hospital and Rotterdam Ophthalmic Institute Home
English
Nederlands
Home
Research output
Profiles
Activities
Press/Media
Research units
Search by expertise, name or affiliation
Neovascular age-related macular degeneration: Insights into treatment
Sankha Amarakoon
Rotterdam Ophthalmic Institute
Research output
:
Types of Thesis
›
Doctoral Thesis
187
Downloads (Pure)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Neovascular age-related macular degeneration: Insights into treatment'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Neovascular Age-related Macular Degeneration (nAMD)
100%
Exudative
100%
Bevacizumab
56%
On Demand
37%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
31%
Fixed-dose Combination
25%
Macula
12%
Treatment Group
12%
Intraretinal
12%
Blood Flow
12%
Phase-resolved Doppler
12%
Doppler OCT
12%
Initial Treatment
12%
Visual Gain
12%
Visual Acuity
6%
VFQ-25
6%
Treatment Efficacy
6%
Randomized Controlled Trial
6%
Retina
6%
Bevacizumab Treatment
6%
Ranibizumab
6%
Intravitreal Ranibizumab
6%
Demand Study
6%
Fundoscopy
6%
Intravitreal Injection
6%
Clinical Care
6%
Quality of Life Instruments
6%
SF-6D
6%
Generic Quality of Life
6%
Treatment Results
6%
Non-inferiority
6%
Clinical Signs
6%
Anti-VEGF Therapy
6%
Visual Acuity Outcome
6%
First Year
6%
Disease Process
6%
Short Form 36 (SF-36)
6%
Novel Technique
6%
Golden Standard
6%
10-year Follow-up
6%
Vison
6%
Registration Trial
6%
Same Patient
6%
Weekly Frequency
6%
Fluid Type
6%
Injection Rate
6%
Chapter 9
6%
Novel Diagnostics
6%
Therapy Frequency
6%
General Introduction
6%
Ophthalmic Patients
6%
Economic Analysis
6%
Pharmacology, Toxicology and Pharmaceutical Science
Wet Macular Degeneration
100%
Bevacizumab
100%
Vasculotropin
54%
Recurrent Disease
27%
Disease
18%
Randomized Controlled Trial
9%
Ranibizumab
9%
Intravitreal Administration
9%
Agents Acting on the Eye
9%
Neuroscience
Age-Related Macular Degeneration
100%
Bevacizumab
100%
Vascular Endothelial Growth Factor
54%
Randomized Controlled Trial
9%
Ophthalmoscopy
9%
Ranibizumab
9%
Biochemistry, Genetics and Molecular Biology
Bevacizumab
100%
Vascular Endothelial Growth Factor
54%
Visual Acuity
36%
Blood Flow
18%
Liquid
9%
Randomized Controlled Trial
9%
Ranibizumab
9%